Getting Mayes on board will prove to be a good move for Advaxis as they move forward. His experience in the healthcare field, more specifically oncology, should be reassuring for shareholders who have doubts about Advaxis. Personal involvement in the company shows that Mayes believes in the technology and its potential.
O'Connor continues to build for the future. Share price, though lagging, will follow. Another move that further validates Advaxis.
News 
Market Data 
Discover 
AI
